A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers.

Adi DiabOmid HamidJohn A ThompsonWilleke RosFerry A L M EskensToshihiko DoiSiwen Hu-LieskovanSamuel J KlempnerBishu GangulyCatherine FleenerXiao WangTenshang JohKai H LiaoShahram Salek-ArdakaniCarrie Turich TaylorJeffrey ChouAnthony B El-Khoueiry

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Ivuxolimab was generally well tolerated with on-target immune activation at clinically relevant doses, showed preliminary antitumor activity, and may serve as a partner for combination studies.

Keyphrases

open label
locally advanced
squamous cell carcinoma
phase ii study
small cell lung cancer
rectal cancer
clinical trial
neoadjuvant chemotherapy
phase ii
phase iii
randomized controlled trial
lymph node
hiv testing
hiv infected
antiretroviral therapy